| B0000 |
2B-(A) |
1 mg |
$114.70 |
| |
C81H137N28o28S FW 1983.23 |
2 mg |
$195.30 |
| |
|
5 mg |
$344.10 |
| |
|
|
|
| B0072 |
2B-(S) |
1 mg |
$114.70 |
| |
C81H137N28O28S FW 1983.23 |
2 mg |
$195.30 |
| |
|
5 mg |
$344.10 |
| |
|
|
|
| B0110 |
Baclofen |
1 g |
$29.50 |
| |
C10H12ClNO2 FW 213.66 [1134-47-0] |
5 g |
$123.00 |
| |
A GABA-b receptor agonist. |
10 g |
$196.90 |
| |
Brogden RN, Speight TM, Avery GS. Drugs 8:1-14 (1974). |
|
|
| |
|
|
|
| |
|
|
|
| B0108 |
Bactenecin, bovine |
0.5 mg |
$193.50 |
| |
C63H118N24O13S2 FW 1483.9 |
1 mg |
$329.70 |
| |
A 12-amino acid cationic antimicrobial peptide from bovine neutrophis found to be |
|
|
| |
cytotoxic to neuronal and glial cells. |
|
|
| |
Wu M, Hancock RE. J Biol Chem. 274:29-35 (1999). |
|
|
| |
Radermacher SW, Schoop VM, Schluesener HJ. J Neurosci Res. 36:657-62 (1993). |
|
|
| |
|
|
|
| B0025 |
Bafilomycin A1 |
50 µg |
$205.10 |
| |
C35H58O9 FW 622.8 [88899-55-2] |
5x50µg |
$758.90 |
| |
Macrolide isolated from Streptomyces sp. that has been shown to decrease |
|
|
| |
multi-drug resistance. It also has shown apoptotic and antibiotic properties. |
|
|
| |
Altan et al. Journal of Experimental Medicine.187:1585 (1998). |
|
|
| |
Montcourrier P et al. Clinical & Experimental Metastasis. 15:382(1997). |
|
|
| |
Martinez-Zaguilan R et al. Biochemical Pharmacology. 57:1037(1999). |
|
|
| |
|
|
|
| B0026 |
Bafilomycin B1 |
1 mg |
$123.00 |
| |
C44H65NO13 FW 815.99 [88899-56-3] |
|
|
| |
Macrolide isolated from Streptomyces sp. that exhibits antibiotic properties. |
|
|
| |
Werner G, Hagenmaier H, Drautz H et al. Journal of Antibiotics. 37:110-7 (1984). |
|
|
| |
|
|
|
| B0133 |
Baicalin |
1 mg |
$55.10 |
| |
C21H18O11 FW 446.36 [21967-41-9] m.p. 223oC |
5 mg |
$215.30 |
| |
Baicalin is a flavonoid found in the radix of Scutellaria baicalensis that |
10 mg |
$301.40 |
| |
has antioxidant activity. It has anti-inflammatory effects, anti-HIV activity, |
|
|
| |
apoptosis induction and inhibition of colon aberrant crypts properties. |
|
|
| |
GAo Z, Huang K, Yang X, Xu H. Biochem Biophys Acta. 1472:643-650 (1999). |
|
|
| |
Lin CC, Shieh DE. Am. J. Chin. Med. 24:31-36 (1996). |
|
|
| |
Kitamura K, Honda M, Yoshizaki H et al. Antiviral Res. 37:131-140 (1998). |
|
|
| |
Wu X, Akatsu H, Okada H. Jpn J Med Sci. Biol. 48:79-87 (1995). |
|
|
| |
|
|
|
| A0248 |
BAM-12P |
1 mg |
$71.70 |
| |
C62H97N21O16S FW 1424.66 |
2 mg |
$121.90 |
| |
Dodecapeptide isolated from bovine adrenal medulla. It is a Pro-Met-enkephalin |
5 mg |
$215.00 |
| |
precursor. |
|
|
| |
Mizuno K, Minamino N, Kangawa K, Matsuo H. Biochem Biophys Res Commun. 29:1482-8 (1980). |
|
|
| |
|
|
|
| A0249 |
BAM-22P |
1 mg |
$164.90 |
| |
C130H184N38O31S2 FW 2839.28 |
2 mg |
$279.60 |
| |
|
5 mg |
$494.60 |
| |
|
|
|
| B0150 |
Bambuterol Hydrochloride |
500 mg |
$96.70 |
| |
C18H29N3O5.HCl FW 403.91 [81732-46-9] |
1 g |
$138.00 |
| |
A bronchodilator. It inhibits plasma cholinesterase during metabolism and |
5 g |
$524.40 |
| |
prolongs suxamethonium-induced neuromuscular blockade. |
|
|
| |
Bang U, Viby-Mogensen J, Wiren JE et al. Acta Anaethesiol Scand. 34:596-9 (1990). |
|
|
| |
Sitar DS, Aoki FY, Warren CP et al. Chest. 103:771-6 (1993). |
|
|
| |
|
|
|
| |
BCNU (See Carmustine) |
|
|
| |
N,N'-Bis(2-chloroethyl)-N-nitrosourea |
|
|
| |
|
|
|
| B1753 |
Benfotiamine |
250 mg |
$33.60 |
| |
S-Benzoylthiamine O-monophosphate |
1 g |
$67.20 |
| |
C19H23N4O6PS FW 466.453 [22457-89-2] |
5 g |
$140.00 |
| |
A lipid-soluble thiamine derivative found in Allium family vegetables such as garlic, onions, |
|
|
| |
leeks and shallots. As a treatment for diabetic neuropathy, benfotiamine is more effective at |
|
|
| |
increasing thiamine levels in blood and tissues than water-soluble salts like the previous vitamin B1. |
|
|
| |
Altern Med Rev.11: 238-242 (2006). |
|
|
| |
Marchetti et. al.Diabetes. 55: 2231-7 (2006). |
|
|
| |
|
|
|
| B1545 |
Benzalkonium Bromide |
100 g |
$55.20 |
| |
[91080-29-4] |
500 g |
$172.50 |
| |
Ulcerative agent. Preservative in most ophthalmic topical solutions. On epithelial conjunctival |
|
|
| |
cells in vitro, cells die by necrosis at high concetrations and by apoptosis at low concentration. |
|
|
| |
Wilmer JL, Burleson FG, Kayama F et al. J Invest Dermatol. 102:915-22 (1994). |
|
|
| |
De Saint Jean M, Brignole F, Bringuier AF et al. Invest Ophthalmol Vis Sci. 40:619-30 (1999). |
|
|
| |
|
|
|
| B1853 |
1,4-Benzoquinone |
100 g |
$24.30 |
| |
C6H4O2 FW 108.09 [106-51-4] |
500 g |
$68.90 |
| |
It is one of the major metabolites of benzene. It causes DNA damage and |
|
|
| |
apoptosis through H2O2 generation in cells. |
|
|
| |
|
|
|
| |
S-Benzoylthiamine O-monophosphate (See Benfotiamine) |
|
|
| |
|
|
|
| B1640 |
Benzydamine Hydrochloride |
5 g |
$28.00 |
| |
C19H23N3O.HCl FW 345.87 [132-69-4] |
25 g |
$106.40 |
| |
Locally acting nonsteroidal anti-inflammatory with local anesthetic and analgesic properties. |
|
|
| |
properties. Prostaglandin synthetase inhibitor. |
|
|
| |
|
|
|
| B1653 |
Benzyl isothiocyanate |
5 g |
$23.30 |
| |
C8H7NS FW 149.22 b.p. 242-243oC [622-78-6] d. 1.125 |
10 g |
$37.30 |
| |
Inhibitor of methylazoxymethanol acetate-induced intestinal carcinogenesis. |
|
|
| |
Sugie S, Okamoto K, Okumura A et al. Carcinogenesis. 8:1555-1560 (1994). |
|
|
| |
|
|
|
| B1654 |
Benzyl selenocyanate |
50 mg |
$50.40 |
| |
C8H7NSe FW 196.11 [4671-93-6] |
100 mg |
$89.60 |
| |
A versatile synthetic organoselenium chemopreventive agent. Found |
500 mg |
$380.80 |
| |
to be effective in several animal tumor model systems. |
|
|
| |
Fiala ES, Sohn OS, Li H et al. Carcinogenesis. 9:1809-1815 (1997). |
|
|
| |
|
|
|
| B1655 |
S-(N-Benzylthiocarbamoyl)-L-cysteine |
500 mg |
$62.40 |
| |
C11H14N2O2S2 FW 270.37 m.p. 191-193°C [35446-36-7 ] |
1 g |
$108.10 |
| |
Cysteine conjugate of benzyl isothiocyanate. |
5 g |
$364.40 |
| |
|
|
|
| B1656 |
Benzyl thiocyanate, 97% |
10 g |
$22.40 |
| |
C7H5NS FW 135.17 [3012-37-1] |
50 g |
$55.40 |
| |
Effective against methylazoxymethanol acetate-induced intestinal carcinogenesis. |
|
|
| |
Sugie S, Okamoto K, Okumura A, Tanaka T, Mori H. Carcinogenesis. 8:1555-1560 (1994). |
|
|
| |
|
|
|
| B1669 |
Berbamine Hydrochloride, 95% |
5 g |
$39.20 |
| |
C37H40N2O6·HCl FW 608.731 [478-61-5] |
10 g |
$67.20 |
| |
A non-steroidal anti-inflammatory that exhibits anti-arrhythmia, anti- |
25 g |
$134.40 |
| |
hypertensive, anti-neoplastic, and antioxidative effects. Berbamine induces Caspaces |
|
|
| |
3 mediated apoptosis of leukemia cells, suggesting that berbamine may be a novel anticancer drug. |
|
|
| |
Sun et.al. Zhonghua Yi Xue Za Zhi. 86: 2246-51 (2006). |
|
|
| |
He Z, Zhao X, Xu R, Wu D. Zhejiang Da Xue Xue Bao Yi Xue Ban. 35: 209-14 (2006). |
|
|
| |
Guo Z, Fu J, Zhongguo Zhong Xi Yi Jie He Za Zhi. 25: 765-8 (2005). |
|
|
| |
|
|
|
| B1870 |
Berberine hydrochloride hydrate |
5 g |
$26.00 |
| |
C20H18NO4+Cl- FW 371.82 [633-65-8] |
10 g |
$34.50 |
| |
It is an isoqinoline alkaloid found in plants. It was shown to have chemopreventive |
|
|
| |
properties against colon tumor formation by inhibiting the enzyme |
|
|
| |
cyclooxygenase-2 (cox-2) and Activator Protein 1 (AP-1 ). |
|
|
| |
Fukuda k et. al. Journal of Ethnoph. 66:227-33 (1999). |
|
|
| |
Fukuda k, Hibiya Y, Mutah M et al. Planta Med. 65:381-3 (1999). |
|
|
| |
|
|
|
| B1769 |
Bergenin |
1 mg |
$68.90 |
| |
C14H16O9.H2O FW 346.3 [477-90-7] |
5 mg |
$249.80 |
| |
Bergenin is an isocoumarin isolated from various medicinal plants. |
10 mg |
$364.80 |
| |
It shows mild anti-HIV activity and has antihepatotoxic and antiulcer activity. |
|
|
| |
Lim HK, Kim HS, Chung MW, Kim YC. J. Ethnopharmacol. 70:69-72 (2000). |
|
|
| |
Goel RK, Maiti RN, Manickam M, Ray AB. Indian J. Exp. Biol. 35:1080-1083 (1997). |
|
|
| |
Liu W. Chung Kuo Chung Yao Tsa Chih. 16:102-104, 128 (1991). |
|
|
| |
|
|
|
| B1668 |
Berteroin, 97% |
25 mg |
$73.00 |
| |
C7H13NS2 FW 175.43 [4430-42-6] |
50 mg |
$126.70 |
| |
|
100 mg |
$217.70 |
| |
|
500 mg |
$732.70 |
| |
|
|
|
| B1874 |
Bestatin Hydrochloride |
1 mg |
$32.90 |
| |
C16H24N2O4.HCl FW 344.87 [65391-42-6] |
5 mg |
$92.80 |
| |
It is a specific inhibitor against aminopeptidase B and leucine aminopeptidase. |
10 mg |
$146.30 |
| |
It has also exhibits a direct antileukemic and antitumor effect against non-small |
|
|
| |
cell cancer through induction of apoptosis. |
|
|
| |
Sekine K, Fujii H., Abe F. Leukemia. 13:729-34 (1999). |
|
|
| |
Ezawa K, Minato K., Dobashi K. Biomed Parmacother. 50:283-9 (1996). |
|
|
| |
|
|
|
| B1876 |
Betamethasone |
100 mg |
$138.00 |
| |
C22H29FO5 FW 392.46 [378-44-9] |
500 mg |
$448.40 |
| |
A Glucocorticoid. It induces gene expression and apoptosis. |
|
|
| |
Hofmann TG, Hehner SP, Bacher S et al. FEBS Lett. 441:441-6 (1998). |
|
|
| |
Kalthoff FS, Chung J, Musser P et al. Clin Exp Immunol. 133:350-9 (2003). |
|
|
| |
|
|
|
| B1879 |
Betamethasone Valerate |
100 mg |
$98.00 |
| |
C27H37FO6 FW 476.58 [2152-44-5] |
500 mg |
$415.00 |
| |
is a moderately potent glucocorticoid steroid with anti-inflammatory and |
|
|
| |
immunosuppressive properties. |
|
|
| |
Sommer, S, British Journal of Dermatology (2002), 147(2), 266-269. |
|
|
| |
|
|
|
| B1878 |
Betamethasone 21-phosphate sodium salt |
250 mg |
$82.90 |
| |
C22H28FNa2O8P FW 516.40 [151-73-5] |
1 g |
$231.80 |
| |
A water soluble, anti-inflammatory glucocorticoid. |
|
|
| |
It has exhibited an antiulcerative effect on colonic lesions. |
|
|
| |
Kitano A, Matsumoto T, Tabata A et al. Nippon Shokakibyo Gakkai Zasshi. 90:24-32 (1993). |
|
|
| |
Faro CJ, Reidelberger RD, Palmer JM. Am J Physiol Regul Integr Comp Physiol. 278:118-24 (2000). |
|
|
| |
|
|
|
| B1898 |
Bezafibrate |
1 g |
$23.50 |
| |
C19H20ClNO4 FW 361.82 [41859-67-0] |
5 g |
$74.60 |
| |
A peroxisome proliferator and hypolipidaemic agent. A derivative of clofibrate. |
25 g |
$245.60 |
| |
It has been shown to be effective in preventing mammary tumors induced by radiation |
|
|
| |
together with DES, possibly by reducing prolactin and triglyceride concentrations. |
|
|
| |
Inano H, Suzuki K, Wakabayashi K. Carcinogenesis. 17:2641-6 (1996). |
|
|
| |
Goll V, Viollon-Abadie C, Nicod L et al. Hum Exp Toxicol. 19:193-202 (2000). |
|
|
| |
|
|
|
| B3203 |
Biapenem |
10 mg |
$39.20 |
| |
C15H18N4O4S FW 350.397 [120410-24-4] |
25 mg |
$67.20 |
| |
A parenteral carbepenem that exhibits antibacterial activities against a wide |
100 mg |
$152.30 |
| |
range of gram-positive and Šnegative bacteria. |
|
|
| |
Aldridge K, Morice N, Schiro D. Antimicrob Agents Chemother. 38: 889-93(1994). |
|
|
| |
|
|
|
| B3209 |
Bicalutamide |
100 mg |
$50.20 |
| |
C18H14F4N2O4S FW 430.37 [90357-06-5] |
250 mg |
$90.90 |
| |
A nonsteroidal antiandrogen which has been shown effective in the treatment of |
1 g |
$273.50 |
| |
prostate cancer. It has also been shown to induce cell death by a pathway that is |
|
|
| |
independent of changes in mitochondrial membrane potential and Bcl-2 actions. |
|
|
| |
Maucher A, von Angerer E. J Canc Res Clin Oncol. 119:669-74 (1993). |
|
|
| |
Lee EC, Zhan P, Schallhom R et al. Cell Death & Differentiation. 10:761-71 (2003). |
|
|
| |
|
|
|
| B3210 |
R-Bicalutamide |
100 mg |
$100.40 |
| |
C18H14F4N2O4S FW 430.37 [113299-40-4] |
250 mg |
$181.90 |
| |
A chiral nonsteroidal antiandrogen which has been shown to inhibit CYP3A4, |
1 g |
$547.00 |
| |
with lesser effect on CYP2C9, 2C19 and 2D6. |
|
|
| |
Cockshott ID. Clin Pharmacokinet. 43: 855-78 (2004). |
|
|
| |
|
|
|
| B3320 |
Bifonazole |
1 g |
$24.90 |
| |
C22H18N2 FW 310.39 [60628-96-8] |
5 g |
$75.90 |
| |
An imidazole antifungal agent and calmodulin antagonist. It causes a reduction |
25 g |
$255.40 |
| |
in glycolysis and ATP levels in B16 melanoma cells. |
|
|
| |
Penso J, Beitner R. Eur J Pharmacol. 342:113-7 (1998). |
|
|
| |
Glass-Marmor L, Morgenstern H, Beiter R. Eur J Pharmacol. 313:265-71 (1996). |
|
|
| |
|
|
|
| B3324 |
Big Endothelin-1 (1-38), human |
0.5 mg |
$365.60 |
| |
C189H282N48O56S5 FW 4282.96 [124363-98-0] |
1 mg |
$621.80 |
| |
A vasoconstrictor peptide that induces slow developing, long-lasting, and strong |
2.5 mg |
$1,096.70 |
| |
vasoconstriction, indicating its physiological importance in vascular homeostasis. |
|
|
| |
Kimura et. al. J Cardiovasc Pharmacol. 13 (Suppl 5): discussion S18 (1989). |
|
|
| |
|
|
|
| B3345 |
Bilobalide |
5 mg |
$112.10 |
| |
C15H18O8 FW 326.30 [33570-04-6] |
10 mg |
$172.10 |
| |
Naturally occurring diterpene from Ginkgo biloba. It has anti-ischemic and |
25 mg |
$344.40 |
| |
anti-convulsant properties. |
|
|
| |
Janssens D, Remacle J, Drieu K, Michiels C. Biochem Pharmacol. 58:109-19 (1999). |
|
|
| |
Sasaki K, Hatta S, Haga M, Ohshika H. Eur J Pharmacol. 367:165-73 (1999). |
|
|
| |
|
|
|
| B3358 |
Biochanin A |
100 mg |
$28.70 |
| |
5,7-Dihydroxy-4'-methoxyisoflavone |
250 mg |
$57.70 |
| |
C16H12O5 FW 284.26 m.p. 210-213oC [491-80-5] |
1 g |
$166.50 |
| |
An isoflavone with anticancer proliferation, differentiation and chemopreventive |
|
|
| |
effects. Inhibits metabolic activation of benzo[a]pyrene. |
|
|
| |
Chae Y.-H, Ho DK, Cassady JM et al. Chem. Biol. Interactions 82: 181-193 (1992). |
|
|
| |
Jing Y, Waxman S. Anticancer Res. 15(4): 1147-1152 (1995). |
|
|
| |
|
|
|
| B3458 |
Biopterin |
5 mg |
$100.80 |
| |
C9H11N5O3 FW 237.22 [22150-76-1] |
10 mg |
$168.00 |
| |
An obligate cofactor of inducible nitric oxide synthase. |
25 mg |
$358.40 |
| |
Weinberg JB, Misukonis MA, Shami PJ et al. Blood 86:1184-95 (1995). |
|
|
| |
|
|
|
| B3278 |
Biotin |
500 mg |
$33.20 |
| |
D-Biotin;Vitamin H |
1 g |
$49.70 |
| |
C10H16N2O3S FW 244.31 [58-85-5] |
5 g |
$213.90 |
| |
A coenzyme that offers three possible binding sites. Used for pretargeted therapy, |
10 g |
$393.30 |
| |
which increases the amount of radioactivity delivered to a cancer cell. |
|
|
| |
Sigel H. Experientia. 37:789-98 (1981). |
|
|
| |
Correa-Gonzalez L, Arteaga de Murphy C, Ferro-Flores G et al. Nucl Med Biol. 30:135-40 (2003). |
|
|
| |
|
|
|
| B3374 |
Bisacodyl |
10 g |
$66.30 |
| |
C22H19NO4 FW 361.39 [603-50-9] |
25 g |
$71.80 |
| |
A diphenolic laxative. It is suggested that intestinal inhibition of (Na+K+) ATPhase activity, |
|
|
| |
increase of mucosal PGE2 content, and possibly also stimulation of adenyl cyclase activity |
|
|
| |
might contribute to the net water accumulation induced by bisacodyl. |
|
|
| |
Farack UM, Nell G. Digestion. 30:191-4 (1984). |
|
|
| |
Rachmilewitz D, Karmeli F, Okon E. Dig Dis Sci. 25:602-8 (1980). |
|
|
| |
|
|
|
| B3373 |
Bisazir |
500 mg |
$59.60 |
| |
Bis(aziridinyl)methylamino phosphine sulfide |
1 g |
$100.70 |
| |
C4H12N3SP FW 177.21 [13687-09-7] |
5 g |
$400.30 |
| |
|
|
|
| B3272 |
Bis(3,5-dibromosalicyl) fumarate |
100 mg |
$16.50 |
| |
C18H8O8Br4 FW 671.87 m.p. 225-228oC [71337-53-6] |
500 mg |
$57.50 |
| |
Potent acylating agent of intracellular hemoglobin that cross-links beta chains |
1 g |
$82.00 |
| |
of hemoglobin. |
5 g |
$164.00 |
| |
Walder JA, Zaugg RH, Walder RY et al. Biochemistry. 18:4265-4270 (1979). |
|
|
| |
Zaugg RH. Walder JA, Walder RY et al. J Biol Chem. 255:2816-21 (1980). |
|
|
| |
|
|
|
| B3275 |
Bis(3,5-dibromosalicyl) succinate |
100 mg |
$16.50 |
| |
C18H10O8Br4 FW 673.89 m.p. 194-196oC [71337-52-5] |
500 mg |
$57.50 |
| |
Potent acylating agent of intracellular hemoglobin. It cross-links beta chains |
1 g |
$82.00 |
| |
of hemoglobin. |
5 g |
$164.00 |
| |
Walder JA, Zaugg RH, Walder RY, Steele JM, Klotz IM. Biochemistry, 18:4265-4270 (1979). |
|
|
| |
Zaugg RH, Walder JA, Walder RY, Steele JM, Klotz IM. J. Biol. Chem., 255:2816-21 (1980). |
|
|
| B3280 |
Bis(salicyl) fumarate |
100 mg |
$16.50 |
| |
C18H12O8 FW 356.29 m.p. 178-180oC |
500 mg |
$57.50 |
| |
Potent acylating agent of intracellular hemoglobin. It cross-links beta chains |
1 g |
$82.00 |
| |
of hemoglobin. |
5 g |
$164.00 |
| |
Zaugg RH, Walder JA, Walder RY et al. J Biol Chem. 255:2816-21 (1980). |
|
|
| |
|
|
|
| B4401 |
Blasticidin S |
25 mg |
$112.90 |
| |
C17H26N8O5 FW 422.44 [2079-00-7] |
50 mg |
$175.60 |
| |
An aminohexosylcytosine nucleoside that inhibits protein synthesis. |
100 mg |
$316.20 |
| |
It has also been shown to induce apoptosis in certain models. |
|
|
| |
Johnson CR, Jiffar T, Fischer UM et al. Leukemia. 17:2140-8 (2003). |
|
|
| |
Petropoulos AD, Xaplanteri MA, Dinos GP et al. J Biol Chem. 279:26518-25 (2004). |
|
|
| |
|
|
|
| B4402 |
Blasticidin S Hydrochloride |
25 mg |
$115.50 |
| |
C17H26N8O5.HCl FW 458.5 [3513-03-9] |
50 mg |
$185.70 |
| |
An aminohexosylcytosine nucleoside that inhibits protein synthesis. |
100 mg |
$294.80 |
| |
It has also been shown to induce apoptosis in certain models. |
|
|
| |
Johnson CR, Jiffar T, Fischer UM et al. Leukemia. 17:2140-8 (2003). |
|
|
| |
Petropoulos AD, Xaplanteri MA, Dinos GP et al. J of Biol Chem. 279:26518-25 (2004). |
|
|
| |
|
|
|
| B4517 |
Bleomycin A5 Hydrochloride |
5 mg |
$261.70 |
| |
Pingyangmycin |
10 mg |
$438.90 |
| |
C57H89N19O21S2.nHCl FW 1440.56 |
25 mg |
$903.70 |
| |
Pingyangmycin is an antitumor antibiotic. It induces apoptosis. |
|
|
| |
Tai KW, Chou MY, Hu CC, Yan, JJ, Chang YC. Oral Oncol. 36:242-7 (2000). |
|
|
| |
Li XT. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao. 12:182-6 (1990). |
|
|
| |
|
|
|
| |
|
|
|
| B4518 |
Bleomycin sulfate |
5 mg |
$206.60 |
| |
C55H84N17O21S3.H2SO4 [9041-93-4] |
10 mg |
$301.40 |
| |
1.5-2.0 Units per mg. |
25 mg |
$602.60 |
| |
A glycopeptide antibiotic consisting of a mixture of bleomycin sulfate salts. |
|
|
| |
Bleomycin A2 is pictured. |
|
|
| |
Lown JW, Sim S-K. Biochem. Biophys. Res. Commun. 77: 1150 (1977). |
|
|
| |
Haidle CW, Lloyd RS. Antibiotics 5: 124 (1979). |
|
|
| |
|
|
|
| B5560 |
BNP (1-32), rat |
0.5 mg |
$164.90 |
| |
C146H239N47O44S3 FW 3453.01 |
1 mg |
$279.60 |
| |
A brain diuretic-natriuretic and vasorelaxant peptide found in the brain and atrium |
2.5 mg |
$494.60 |
| |
of rats. |
|
|
| |
Kojima M, Minamino N, Kangawa K, Matsuo H. Biochem Biophys Res Commun. 159: 1420-6 (1989). |
|
|
| |
|
|
|
| B5561 |
BNP (1-32), human |
0.5 mg |
$164.90 |
| |
C143H244N50O42S4 FW 3464.1 |
1 mg |
$279.60 |
| |
A brain natriuretic peptide secreted by the human heart in response to cardiac |
2.5 mg |
$494.60 |
| |
volume or pressure. |
|
|
| |
Al-Meslmani BM, Fahoum SK, Shamia MG. Clin Lab. 53: 35-9 (2007). |
|
|
| |
|
|
|
| B5608 |
Boc-FAAGRK-AMC |
20 mg |
$573.40 |
| |
C44H63N11O6 FW 906.0 |
|
|
| |
|
|
|
| |
|
|
|
| B5609 |
Boc-GRR-AMC |
20 mg |
$385.30 |
| |
C29H44N10O7 FW 644.7 |
|
|
| |
|
|
|
| |
|
|
|
| B5610 |
Boc-PRR-AMC |
20 mg |
$385.30 |
| |
C32H48N10O7 FW 684.8 |
|
|
| |
|
|
|
| |
|
|
|
| B5611 |
Boc-RRR-AMC |
20 mg |
$385.30 |
| |
C33H53N13O7 FW 743.8 |
|
|
| |
|
|
|
| |
|
|
|
| B5648 |
Bombesin |
1 mg |
$28.70 |
| |
C71H111N24O18S FW 1619.86 [31362-50-2] |
2 mg |
$48.40 |
| |
A gut tetradecapeptide with the ability to stimulate the release of numerous |
5 mg |
$86.00 |
| |
hormones. It inhibits growth of pancreatic ductal adenocarcinoma (H2T) in nude mice. |
|
|
| |
Chen LW, Hsu CM, Huang JK et al. J Formos Med Assoc. 99:491-8 (2000). |
|
|
| |
Farre A, Ishizuka J, Gomez G et al. Pancreas. 9:652-6 (1994). |
|
|
| |
|
|
|
| B5649 |
[Tyr4] Bombesin |
1 mg |
$35.80 |
| |
C74H108N24O19S FW 1669.9 |
2 mg |
$60.90 |
| |
|
5 mg |
$107.50 |
| |
|
|
|
| B5753 |
Bongkrekic acid |
100 µg |
$307.30 |
| |
C28H38O7 FW 486.60 [11076-19-0] |
|
|
| |
A mitochondrial permeability transition pore blocker. It has been shown to inhibit apoptosis |
|
|
| |
by preventing PARP cleavage and DEVDase activity. |
|
|
| |
Yoon HS, Moon SC, Kim ND et al. Biochem Bioph Res Co. 276:151-6 (2000). |
|
|
| |
Zamora M, Granell M, Mampel T et al. FEBS Letters. 563:155-60 (2004). |
|
|
| |
|
|
|
| B5874 |
Bosutinib |
10 mg |
$110.00 |
| |
C26H29Cl2N5O3 FW 530.45 [380843-75-4] |
25 mg |
$215.00 |
| |
Bosutinib is a tyrosine kinase inhibitor undergoing research for use in the |
100 mg |
$700.00 |
| |
treatment of cancer. |
|
|
| |
Vultur, A. Molecular Cancer Therapeutics (2008), 7(5), 1185-1194. |
|
|
| |
Vultur, Adina Molecular Cancer Therapeutics (2008), 7(5), 1185-1194. |
|
|
| |
|
|
|
| |
Bothrops alternatus (See snake venom) |
|
|
| |
|
|
|
| |
Bothrops neuwiedi diporus (See snake venom) |
|
|
| |
|
|
|
| B6800 |
Bradykinin triacetate |
10 mg |
$35.80 |
| |
C50H73N15O11 FW 1060.22 [5979-11-3] |
20 mg |
$60.90 |
| |
A pro-inflammatory polypeptide that is an important mediator of hyperalgesia, |
50 mg |
$107.50 |
| |
inflammatory diseases, asthma and cancer. It has been shown to possess |
|
|
| |
potent anti-cancer activities in both in vitro and in vivo cancer models. |
|
|
| |
Stewart JM. Curr Pharm Des. 9:2036-42 (2003). |
|
|
| |
Sharma JN, Al-Dhalmawi GS. Drugs. 6:581-6 (2003). |
|
|
| |
|
|
|
| B6802 |
Bradykinin (1-3) |
5 mg |
$35.80 |
| |
C16H28N6O4 FW 368.4 |
10 mg |
$60.90 |
| |
|
25 mg |
$107.50 |
| |
|
|
|
| B6803 |
Bradykinin (1-5) |
5 mg |
$35.80 |
| |
C27H40N8O6 FW 572.67 |
10 mg |
$60.90 |
| |
|
25 mg |
$107.50 |
| |
|
|
|
| B6804 |
Bradykinin (1-6) |
5 mg |
$35.80 |
| |
C30H45N9O8 FW 659.75 |
10 mg |
$60.90 |
| |
|
25 mg |
$107.50 |
| |
|
|
|
| B6805 |
Bradykinin (1-7) |
5 mg |
$35.80 |
| |
C35H52N10O9 FW 756.87 |
10 mg |
$60.90 |
| |
|
25 mg |
$107.50 |
| |
|
|
|
| B6806 |
Bradykinin (2-9) |
5 mg |
$35.80 |
| |
C44H61N11O10 FW 904.04 |
10 mg |
$60.90 |
| |
|
25 mg |
$107.50 |
| |
|
|
|
| B6807 |
Bradykinin [Des-Arg9] |
5 mg |
$43.00 |
| |
C44H61N11O10 FW 904.04 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| B6808 |
Bradykinin [Des-Pro2] |
5 mg |
$43.00 |
| |
C45H66N14O10 FW 963.12 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| B6809 |
Bradykinin [DPhe7] |
1 mg |
$28.70 |
| |
C54H75N15O11 FW 1110.29 |
2 mg |
$48.40 |
| |
|
5 mg |
$86.00 |
| |
|
|
|
| B6810 |
Bradykinin [Hyp3] |
0.5 mg |
$43.00 |
| |
C30H72N15O10 FW 1077.23 |
1 mg |
$73.50 |
| |
|
2.5 mg |
$129.00 |
| |
|
|
|
| B6811 |
[Tyr8] Bradykinin |
5 mg |
$50.20 |
| |
C50H73N15O12 FW 1076.23 |
10 mg |
$86.00 |
| |
|
50 mg |
$150.50 |
| |
|
|
|
| B6812 |
Bradykinin Potentiator B |
5 mg |
$43.00 |
| |
C56H91N15O13 FW 1182.46 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| B6813 |
Bradykinin Potentiator C |
5 mg |
$43.00 |
| |
C51H77N11O13 FW1052.26 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| B3346 |
Brain injury-derived Neurotrophic Peptide (3) |
1 mg |
$107.50 |
| |
BINP |
2 mg |
$182.80 |
| |
C62H101N17O19 FW 1388.58 |
5 mg |
$322.60 |
| |
|
|
|
| B6801 |
Brassinin |
50 mg |
$86.10 |
| |
C11H12N2S2 FW 236.36 m.p. 132-133oC [105748-59-2] |
100 mg |
$137.80 |
| |
A phytoalexin found in Chinese cabbage. An effective inhibitor of stage two skin |
250 mg |
$286.90 |
| |
carcinogenesis. An inducer of Phase II enzymes and inhibitor of chemically induced |
|
|
| |
carcinogenesis. |
|
|
| |
Mehta RG, Liu J, Constantinou A et al. Carcinogenesis 16: 399-404 (1995). |
|
|
| |
|
|
|
| B6816 |
Brefeldin A |
5 mg |
$129.20 |
| |
C16H24O4 FW 280.36 |
10 mg |
$201.50 |
| |
Macrolide possessing antifungal, antiviral and antitumor properties. |
|
|
| |
Misumi, Y., et al., J. biol. Chem. 261:11398 (1986). |
|
|
| |
Mordente, J.A., Konno, S., Chen, Y. et al J. Urol 159:275-9 (1998). |
|
|
| |
|
|
|
| B6935 |
Brivudine |
10 mg |
$140.00 |
| |
C11H12BrN2O5 Mol. Wt: 332.13 [69304-47-8] |
25 mg |
$260.00 |
| |
An antiviral drug used in the treatment of herpes zoster. |
100 mg |
$750.00 |
| |
Abraham, S. British Journal of Dermatology (2006), 154(2), 365-367. |
|
|
| |
|
|
|
| B6957 |
Bromhexine Hydrochloride |
100 g |
$55.20 |
| |
C14H20Br2N2.HCl FW 412.60 [611-75-6] |
500 g |
$172.50 |
| |
A mucolytic agent. Exerts both a secretagogic action on submucosal glands |
|
|
| |
and a mucolytic action toward acid glycoproteins inside cells in vivo. |
|
|
| |
Takeda H, Abe Y, Misawa M et al. Jpn J Pharmacol. 35:445-50 (1984). |
|
|
| |
Gotz VH. Arzneimittelforschung. 25:607-15 (1975). |
|
|
| |
|
|
|
| B6856 |
5-Bromo-2'-deoxyuridine |
250 mg |
$24.00 |
| |
C9H11BrN2O5 FW 307.11 m.p. 193-197oC [59-14-3] |
500 mg |
$38.50 |
| |
|
1 g |
$65.00 |
| |
|
5 g |
$211.10 |
| |
|
|
|
| B6857 |
4'-Bromoflavone |
1 g |
$77.60 |
| |
C15H9BrO2 FW 301.13 |
5 g |
$258.20 |
| |
A potent Phase II detoxifying enzyme inducer. Inhibits DMBA-induced mammary |
10 g |
$344.40 |
| |
tumorigenesis in the rat. |
|
|
| |
Song, L. L., Kosmeder, J.W., Lee, S.K., et al Cancer Res. 59:578-585 (1999). |
|
|
| |
|
|
|
| B7058 |
Brompheniramine |
10 mg |
$120.00 |
| |
C16H19BrN2 Mol. Wt: 319.24 [86-22-6] |
25 mg |
$220.00 |
| |
Halogenated alkylamine antihistamine. Antidepressant properties due to |
100 mg |
$680.00 |
| |
reuptake inhibition of seratonin. Has analgesic-sparing effects on opiod analgesics |
|
|
| |
Park, Sang-Joon. Journal of Applied Toxicology (2008), 28(2), 104-111. |
|
|
| |
|
|
|
| B6998 |
Bryostatin 1 |
10 µg |
$181.90 |
| |
C47H68O17 FW 905.03 [83314-01-6] |
25 µg |
$308.10 |
| |
It is a partial Protein kinase C (PKC) agonist that has potent antitumor |
|
|
| |
and immunomodulatory activity. It also enhances cytotoxicity of most |
|
|
| |
chemotherapeutic agents. |
|
|
| |
Caponigro F, French RC, Kaye SB. Anticancer Drugs. 8:26-33 (1997). |
|
|
| |
Dowlati A et. al. American Society of Clinical Oncology Online (2000). |
|
|
| |
Koutcher J A et. al. Clinical Cancer Research. 6:1498-1507 (2000). |
|
|
| |
|
|
|
| B6999 |
Bryostatin 2 |
10 µg |
$215.30 |
| |
C45H66O16 FW 863.00 [87745-28-6] |
25 µg |
$409.90 |
| |
A macrocyclic lactone with anti-tumor properties. Competes with phorbol ester |
|
|
| |
binding to protein kinase C (PKC)(K i = 3.4 nM) and antagonizes phorbol ester |
|
|
| |
action. Also exhibits growth inhibitory activity against several human cancer cell |
|
|
| |
lines (GI 50 1.8 - 170 ng/ml). |
|
|
| |
Dale, I.L., et al. Cancer Res. 49, 3242 (1989).Wender, P.A., et al. Proc. Natl. Acad. Sci. USA . 95: 6624 (1998). |
|
|
| |
|
|
|
| B8010 |
Buccalin |
1 mg |
$43.00 |
| |
C45H72N12O15S FW 1053.20 |
2 mg |
$73.50 |
| |
A modulatory neuropeptide. |
5 mg |
$129.00 |
| |
Cropper EC, Miller MW, Tenenbaum R et al. Proc Natl Acad Sci USA. 85:6177-81 (1988). |
|
|
| |
|
|
|
| B8112 |
Budesonide |
100 mg |
$39.20 |
| |
C25H34O6 FW 430.53 [51333-22-3] MP: 226oC |
250 mg |
$112.00 |
| |
A glucocorticoid steroidal anti-inflammatory agent used for the treatment of |
1 g |
$313.60 |
| |
asthma, non-infectious rhinitis and nasal polyposis. Budesonide is also know to |
|
|
| |
be a potent chemopreventive agent in mice by decreasing the size of lung tumors, |
|
|
| |
reversing DNA hypomethylation and altering mRNA gene expression. |
|
|
| |
Pereira MA, Tao L, Liu Y, Li L, Steele VE, Lubet RA. Int J Cancer.120:1150-3 (2007). |
|
|
| |
|
|
|
| B8144 |
Bulleyaconitine A |
10 mg |
$41.10 |
| |
C35H49NO10 FW 643.76 107668-79-1] |
100 mg |
$239.60 |
| |
An active principle component from Aconitum bulleyanum Diel has analgesic property. |
|
|
| |
Tang XC, Liu XJ, Lu WH. Acta Pharm Sinica. 21:886-891 (1986). |
|
|
| |
|
|
|
| B8248 |
Bumetanide |
250 mg |
$44.80 |
| |
C17H20N2O5S FW 364.42 [28395-03-1] |
1 g |
$123.20 |
| |
Diuretic of the sulfamyl category to treat heart failure. An alternative to furosemide |
|
|
| |
Dzhala, V. Annals of Neurology (2008), 63(2), 222-235. |
|
|
| |
Lu, K. Neurological Research (2007), 29(4), 404-409. |
|
|
| |
Delpy A. J. of physiology (2008), 586(4), 1059-75. |
|
|
| |
|
|
|
| B8261 |
Bupivacaine Free Base |
1 g |
$56.00 |
| |
C18H28N2O FW 288.43 [38396-39-3] |
5 g |
$95.20 |
| |
Local anesthetic which binds to the intracellular portion of sodium channels and |
25 g |
$364.00 |
| |
blocks sodium influx into the nerve cells |
|
|
| |
Coskuner, I. European Journal of Anaesthesiology (2007), 24(6), 535-540. |
|
|
| |
Kucukguclu, S. European Journal of Anaesthesiology (2008), 25(4), 307-313 |
|
|
| |
Lee Sung-Jin. Anesthesia and analgesia (2008), 107(3), 824-7 |
|
|
| |
|
|
|
| B8262 |
Bupivacaine Hydrochloride |
1 g |
$27.70 |
| |
C18H28N2O.HCl.H2O FW 342.91 [14252-80-3] |
5 g |
$93.90 |
| |
Local anesthetic with a cytotoxic effect on muscle fibers. Inhibits TREK-1 |
25 g |
$345.00 |
| |
channels and depolarizes the cell membrane. |
|
|
| |
Punke MA, Licher T, Pongs O et al. Anesth Analg. 96:1665-73 (2003). |
|
|
| |
Nonaka I, Fujita T, Sugita H. Muscle Nerve. 7:400-7 (1984). |
|
|
| |
|
|
|
| B8363 |
Bupropion Hydrochloride |
50 mg |
$72.80 |
| |
C13H18ClNO.HCl FW 276.2 [31677-93-7] |
250 mg |
$190.40 |
| |
A typical anti-depressant and anti-smoking aid that acts as a norepinephrine and |
1 g |
$476.00 |
| |
dopamine reuptake inhibitor and nicotine antagonist. |
|
|
| |
David, S. Nicotine & Tobacco Research (2007), 9(12), 1251-1257. |
|
|
| |
Piper, M. E. Nicotine & Tobacco Research (2007), 9(9), 947-954. |
|
|
| |
Dhir, A. European Journal of Pharmacology (2007), 568(1-3), 177-185. |
|
|
| |
|
|
|
| B8271 |
Bursin |
5 mg |
$35.80 |
| |
C14H25N7O3 FW 339.39 [60267-34-7] |
10 mg |
$60.90 |
| |
A tripeptide isolated from avian bursa of Fabricius that selectively induces |
25 mg |
$107.50 |
| |
differentiation in B precursor cells nut to T precursor cells. |
|
|
| |
Audhya T, Viamontes G, Babu U, Goldstein G. Scand J Immunol. 31: 199-204 (1990). |
|
|
| |
|
|
|
| B8274 |
Buspirone Hydrochloride |
1 g |
$41.40 |
| |
C21H31N5O2.HCl FW 421.97 |
5 g |
$138.00 |
| |
An azaspirodecanedione that has anxiolytic actions. Affects dopaminergic, serotonergic and |
|
|
| |
noradrenergic pathways, as well as the GABA-benzodiazepine receptor chloride ionophore complex. |
|
|
| |
Skolnick P, Paul SM, Weissman BA. Pharmacotherapy. 4:308-14 (1984). |
|
|
| |
Dringenberg HC, Kornelsen RA, Vanderwolf CH. Pharmacol Biochem Behav. 49:741-6 (1994). |
|
|
| |
|
|
|
| B7973 |
Busulfan |
10 g |
$29.80 |
| |
C6H14O6S2 FW 246.30 m.p. 114-117oC [55-98-1] |
25 g |
$57.50 |
| |
A DNA alkylating agent used as an antitumor drug. Effective in chronic myelocytic leukemia. |
|
|
| |
Fulmer Shealy Y. In "Cancer Chemotherapeutic Agents" Foye WO, Ed., (1995). |
|
|
| |
ACS Professional Reference, pp. 149-153, (1995). |
|
|
| |
|
|
|
| B8278 |
Butoconazole nitrate |
100 mg |
$30.00 |
| |
C19H18Cl3N3O3S- Mol. Wt:474.79 [64872-77-1] |
250 mg |
$48.00 |
| |
An imidazole antifungal used in gynecology. |
1 g |
$150.00 |
| |
Brown, D. Journal of Reproductive Medicine (1999), 44(11), 933-938. |
|
|
| |
|
|
|
| B8174 |
Butylated Hydroxyanisole |
5 g |
$20.20 |
| |
C11H16O2 FW 180.24 |
50 g |
$26.00 |
| |
An antioxidant that is a mixture of 2-tert-butyl-4-methoxyphenol and 3-tert- |
100 g |
$37.90 |
| |
butyl-4-methoxy phenol. It induces phase II detoxifying enzymes that inhibit |
|
|
| |
the action of carcinogens. Dietary BHA induces forestomach tumors. |
|
|
| |
Ito N, Hirose M. Adv. Cancer Res. 53:247-302 (1989). |
|
|
| |
Ito N, Fukushima S, Tsuda H. CRC Crit Rev Toxicol. 15:109-150 (1985). |
|
|
| |
|
|
|
| B7977 |
Butylated hydroxytoluene (BHT) |
100 g |
$20.70 |
| |
C15H24O FW 220.35 m.p. 69-70oC [128-37-0] |
500 g |
$50.40 |
| |
An antioxidant shown to be chemopreventive against a variety of |
|
|
| |
carcinogens. Low doses have a modulating effect on liver and bladder carcinogenesis. |
|
|
| |
Williams GM, Tanaka T, Maruyama et al. Cancer Res. 51:6224-6230 (1991). |
|
|
| |
|
|
|
| B8070 |
2-tert-Butyl-4-hydroxyanisole, 99% |
100 mg |
$60.10 |
| |
C11H16O2 FW 180.25 [88-32-4] |
500 mg |
$172.80 |
| |
Minor isomer of BHA mixture. It has different biological activity than |
1 g |
$270.00 |
| |
the 3-BHA isomer. |
|
|
| |
Lam LKT, Pai RP, Wattenberg LW. J Med Chem. 20:569-571 (1979). |
|
|
| |
Ito N, Hirose M, Urata Y et al. Gann. 75:471-474 (1984). |
|
|
| |
|
|
|
| B8071 |
3-tert-Butyl-4-hydroxyanisole, 99% |
10 g |
$119.80 |
| |
C11H16O2 FW 180.25 m.p. 58-60oC [121-00-6] |
50 g |
$402.90 |
| |
Antioxidant used to stabilize fatty food. It was found to inhibit chemically-induced |
|
|
| |
tumor formation in animals. Under high dose conditions it was carcinogenic |
|
|
| |
to the forestomach of rodents. |
|
|
| |
Ito N, Hirose M. Adv. Cancer Res. 53:247-302 (1989). |
|
|
| |
Ito N, Fukushima S, Tsuda H. CRC Crit Rev Toxicol. 15:109-150 (1985). |
|
|
| |
WattenbergLW,Lam LKT.in"Inhibition of Tumor Induction and Development". M.S.ZedeckandM.Lipkin,eds. |
|
|
| |
pp. 1-22. Plenum Press, N.Y. (1981). |
|
|
| |
Fukuda K et. al. Journal of Ethnoph. 66:227-33 (1999). |
|
|
| |
Fukuda K, Hibiya Y, Mutah M et al. Planta Med. 65:381-3 (1999). |
|
|
| |
|
|
|
| B8072 |
3-tert-Butyl-5-methoxy-catechol |
10 mg |
$67.30 |
| |
C11H16O3 FW 196.25 m.p. 95-96oC [80284-15-7] |
50 mg |
$204.10 |
| |
Cytotoxic agents to P388 and KB cells. |
100 mg |
$359.90 |
| |
Lam LKT, Garg P, Swanson SM, Pezzuto JM. J Pharm Sci. 77: 393-5 (1988). |
|
|
| |
|
|
|
| B8073 |
4-tert-Butyl-5-methoxy-catechol |
10 mg |
$77.10 |
| |
C11H16O3 FW 196.25 m.p. 89-900C [91352-66-8] |
50 mg |
$239.90 |
| |
Cytotoxic agents to P388 and KB cells. |
100 mg |
$419.60 |
| |
Lam LKT, Garg P, Swanson SM, Pezzuto JM. J Pharm Sci. 77: 393-5 (1988). |
|
|
| |
|
|
|
| B8074 |
3-tert-Butyl-5-methoxy-1, 2-quinone |
50 mg |
$108.10 |
| |
C11H14O3 FW 194.25 m.p. 73-74oC [2940-63-8] |
100 mg |
$191.90 |
| |
Cytotoxic agents to P388 and KB cells. |
500 mg |
$618.60 |
| |
Lam LKT, Garg P, Swanson SM, Pezzuto JM. J Pharm Sci. 77: 393-5 (1988). |
|
|
| |
|
|
|
| B8075 |
4-tert-Butyl-5-methoxy-1, 2-quinone |
50 mg |
$156.00 |
| |
C11H14O3 FW 194.25 m.p. 92-95oC [36122-03-9] |
100 mg |
$276.00 |
| |
Cytotoxic agents to P388 and KB cells. |
500 mg |
$887.00 |
| |
Lam LKT, Garg P, Swanson SM, Pezzuto JM. J Pharm Sci. 77: 393-5 (1988). |
|
|
| |
|
|
|
| B8176 |
2-n-Butylthiophene, 97% |
5 g |
$60.10 |
| |
C8H12S FW 140.25 b.p. 181-1820C [1455-20-5] |
10 g |
$110.40 |
| |
An inhibitor of DMH-induced aberrant crypt formation in colon. |
|
|
| |
Lam LKT, Zhang J. Carcinogenesis. 12:2311-2315 (1995). |
|
|
| |
|
|
|
| B8275 |
n-Butyric acid |
10 ml |
$30.90 |
| |
C4H8O2 FW 88.11 |
100 ml |
$43.10 |
| |
Has chemopreventive activity against colon cancer by inducing apoptosis. |
|
|
| |
Kellof G J et al. Journal of Cellular Biochemistry-Supplement. 20:1-24 (1994). |
|
|
| |
|
|
|
| B8276 |
Butyric acid sodium salt |
5 g |
$82.50 |
| |
Sodium butanoate |
25 g |
$192.90 |
| |
C4H7NaO2 FW 110.09 [156-54-7] |
|
|
| |
A potent inhibitor of cell growth and differentiation inducer. It is shown that in |
|
|
| |
P53-mutated human colon cancer cells, butyrate activates the WAF1 promoter and induces |
|
|
| |
WAF1 protein production, which is an inhibitor of cyclin-dependent kinases. |
|
|
| |
Bartram HP, Scheppach W, Englert S et al. J Parenter Entera Nutr. 19:182-6 (1995). |
|
|
| |
Nakano K, Yamagashi H, Oka T, Sakai T. Nippon Geka Gakkai Zasshi. 99:373-8 (1998). |
|
|
| |
|
|
|